Galderma Standardizes on Medidata Rave for Global Dermatology Trials

Galderma Standardizes on Medidata Rave for Global Dermatology Trials

Knowledge Transfer Program Allows Leading Dermatological Company to
Independently Build, Manage and Execute Medidata Rave-Enabled Trials


NEW YORK, N.Y. - October 13, 2010 - Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that one of the world's leading dermatology companies, Galderma, has standardized on the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform.


Based in Lausanne, Switzerland with a presence in 65 countries, Galderma operates one of the world's largest R&D facilities dedicated exclusively to developing treatments for dermatological conditions. These state-of-the-art laboratories, located in Sophia Antipolis, France, are complemented by development centers in Princeton, New Jersey and Tokyo, Japan. With an ongoing need to conduct an expanding number of global clinical trials, Galderma's data management team conducted an extensive, six-month evaluation of three vendors before selecting Medidata Solutions. The team cited Medidata Rave's ability to support hybrid paper-and-electronic data studies, strong standing among the industry's leading CROs and global language capabilities as key reasons for its selection.


"Medidata's track record executing global trials across all trial phases, coupled with their professionalism, proactivity and responsiveness, was critical to our rollout of the Rave solution," said Francis Gon, head of Global Data Management at Galderma. "Medidata's training and eLearning tools also made it easy for us to take the solution in-house and begin to independently build and execute studies in any phase and in multiple languages."


"Galderma's strategic approach to the implementation of Medidata Rave will maximize its ROI and clinical development efficiencies," said Glen de Vries, President, Medidata Solutions. "Moving quickly through the Medidata Rave Knowledge Transfer process has allowed Galderma to take even greater control of its most valuable asset-its clinical data-and provide unmatched visibility into the direction and success of its growing pipeline."

About Galderma
Galderma's ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians. A fully-integrated specialty pharmaceutical company, Galderma was founded in 1981 and has over 3000 employees actively collaborating with doctors, scientists, research institutes, universities, and patient advocacy groups who all share a commitment to improving the health of skin. With approximately 20% of sales invested each year to discover and develop new products and access innovative technologies, Galderma's laboratory in Sophia-Antipolis, France, is one of the largest R&D facilities in the world dedicated exclusively to dermatology. The company's extensive portfolio of products is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and skin senescence. Leading brands include Epiduo, Differin, Oracea, MetroGel, Cetaphil, Tetralysal, Loceryl, Clobex, Tri-Luma, Silkis, Vectical, Dysport and Azzalure.

About Medidata Solutions Worldwide
Medidata Solutions ( is a leading global provider of SaaS-based clinical development solutions that enhance the efficiency of customers' clinical trials. For over 10 years, Medidata has consistently brought next-generation innovation to the life science industry to lower the total cost of clinical development through informed trial planning and management, optimized clinical processes and platform interoperability. Medidata's advanced solutions address key functions throughout the clinical development process including protocol development (Medidata Designer®), trial planning and management (Medidata Grants Manager®, Medidata CRO Contractor®), user and learning management (iMedidataTM), randomization and trial supply management (Medidata BalanceTM), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), Serious Adverse Events capture (Medidata Rave Safety Gateway) and clinical data capture, management and reporting (Medidata Rave®). Our diverse customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Susan McCarron
Lois Paul & Partners
[email protected]